AUTHORS
Jennifer Effie Amengual, MD, Chih-Ting Yang2, Aung M. Tun, MD3, Ted Piorczynski, PhD4, Jan Beumer5, Julianne L Holleran6, Marc S. Hoffmann, MD7, Yun Kyoung Tiger, MD, PhD8, Joanna M Rhodes, MD, MSCE9, Matthew J Matasar, MD, MS10, Harsh Rohit Shah, DO11, Lindsey Fitzgerald, MD12, Joseph Tuscano13, Victor Yazbeck, MD14, Tarsheen Sethi, MD15, Barbara Pro, MD16, Hua-Jay Jeffery Cherng, MD17, Seda S. Tolu, MD18, Yu Shyr19, Naomi Sender20, Sarah Sedycias21, Megan Nieman22, Diane Durecki23, Steven Gore, MD24, Lorraine Pelosof, MD, PhD25, Richard Piekarz, MD, PhD26
AFFILIATIONS
1 Columbia University Irving Medical Center, New York, New York, United States
2 Vanderbilt University, Nashville, Tennessee, United States
3 University of Kansas, Lawrence, Kansas, United States
4 Columbia University Irving Medical Center, New York, New York, United States
5 Johns Hopkins University, Baltimore, Maryland, United States
6 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
7 University of Kansas, Lawrence, Kansas, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Rutgers University, New Brunswick, New Jersey, United States
10 Rutgers University, New Brunswick, New Jersey, United States
11 University of Utah Health, Salt Lake City, Utah, United States
12 University of Utah Health, Salt Lake City, Utah, United States
13 UC Davis Health, Sacramento, California, United States
14 VCU-Compass Plaza, Richmond, Virginia, United States
15 Yale University, New Haven, Connecticut, United States
16 Columbia University Irving Medical Center, New York, New York, United States
17 Columbia University Irving Medical Center, New York, New York, United States
18 Columbia University Irving Medical Center, New York, New York, United States
19 Vanderbilt University, Nashville, Tennessee, United States
20 Columbia University Irving Medical Center, New York, New York, United States
21 Columbia University Irving Medical Center, New York, New York, United States
22 Columbia University Irving Medical Center, New York, New York, United States
23 Yale University, New Haven, Connecticut, United States
24 National Cancer Institute, Bethesda, Maryland, United States
25 National Cancer Institute, Bethesda, Maryland, United States
26 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
ABSTRACT
CTEP 10500 was a Phase 1/Expansion study of tazemetostat (TAZ) plus belinostat (BELINO) for R/R NHL (NCT05627245). The phase 1 dose escalation enrolled all NHL subtypes across 3 dose levels: DL1 TAZ 600mg PO BID + BELINO 750mg/m2 IV D1-5; DL2 TAZ 800mg PO BID + BELINO 750mg/m2 IV D1-5; and DL3 TAZ 800mg PO BID + BELINO 1000mg/m2 IV D1-5 on a 21-day cycle. The expansion allowed subjects with germinal center large B cell, follicular, and T cell lymphomas (TCL) at the RP2D.
Thirty-five subjects registered and 7 subjects were excluded (3 screen failures, 4 logistical reasons). Twenty-eight subjects enrolled and received study drugs. The median age was 68y (31-88); 20 were male, 19 White, 7 Black, 1 American Indian/Alaska Native, 1 unknown race; 3 Hispanic. ECOG PS was 0 for 7, 1 for 16, 2 for 5. Median number of prior therapies was 3 (1-6). Six subjects had prior autoSCT, 2 alloSCT, and 3 CAR T cell therapy. Twenty-two subjects had TCL of varied subtypes (PTCL NOS 12, CTCL/SS 5, transformed MF 2, ATLL 1, ALK+ALCL 1, AITL 1) and 6 had LBCL (transformed iNHL 2, PTLD-HGBCL 1). Insurance coverage included medicare in 9, private in 9, medicare+other in 4, medicaid in 3, and veterans sponsored in 1.
There were 6 subjects enrolled at DL1, 3 at DL2, 19 at DL3, 13 of whom enrolled on the expansion. The RP2D was determined to be TAZ 800mg and BELINO 1000mg/m2. There was 1 DLT: G4 thrombocytopenia that occurred in DL1. Most AEs were G1/2; the most frequent including nausea 37%, fatigue and anemia 32%, creatinine increased, constipation and diarrhea 25%, dizziness and neutrophil count decrease 21%. The most common TRAEs were G1/2 and included: nausea 36%, fatigue 21%, dysgeusia 18%, vomiting 14%, diarrhea, white blood cell count decrease and neutrophil count decrease all 11%. The ³G3 TRAE included lung infection, thrombocytopenia and anemia in 2 subjects each and fever, AST increase, neutrophil count decreased and diarrhea in 1 subject each. There were 21 SAEs with lung infection in 2 and the rest occurring in 1 subject each. Only 6 SAEs were considered to be treatment related. There were 6 deaths, all considered unrelated to treatment: 1 COVID-19 infection, 1 stroke, 4 disease progression.
In the 28 subjects who received study drugs, the 12m PFS and OS rates were 21% and 54%. Twenty-three were evaluable for response (4 at DL1, 3 at DL2, 16 at DL3+expansion). The reasons for being non-evaluable for response included: toxicity prior to start of cycle 2 and removal from study (n=3), and early study closure due to the sponsor’s withdrawal of TAZ with transition to SOC therapy prior to disease assessment (n=2). The best ORR was 43% (10/23) with 26% CRs (6/23), 17% PRs (4/23), 22% with stable disease (5/23) and 35% with PD (8/23).
There were 22 subjects with TCL. The mPFS was 4.1m and mOS was NR. Treatment was discontinued early for 7 due to withdrawal of TAZ (n=5) and transition to consolidative SCT following remission (n=2). Among the TCL population, there were 19 evaluable subjects and responses were similar across all 3 dose levels. For subjects with TCL, the ORR was 53% (10/19) with 32% CRs (6/19), 21% PRs (4/19), and 21% PD (4/19). There were 5 with stable disease (26%) for a disease control rate to 79% (15/19). The mDOR was 2.8m (1.8-26.3+m).
Pharmacokinetic data for TAZ was evaluated in 21 subjects across the dose levels in combination with BELINO. Observed TAZ PK align with prior literature: at 800 mg Cmax 789 vs 829 µg/L; tmax 2.0 vs 1-2 h; t½ 2.9 vs 3-4.6 h; Cmin 86 vs 77-95 µg/L and CL/F 242 vs 117-274 L/h. Pharmacodynamic data is forthcoming.
This Phase 1/Expansion study of dual epigenetic therapy, TAZ plus BELINO, was safe and well tolerated with no secondary malignancies observed. In the TCL population, though small and heterogeneous, the ORR of 53%, CRR of 32% and disease stabilization rate of 79% mirrors results observed in doublet studies such as romidepsin plus either azacitidine or duvelisib. Treatment discontinued early due to the sponsor’s withdrawal of TAZ (not study-specific toxicity) likely impacted DOR, PFS and OS. Continued treatment may have improved clinical benefit. Response rates observed with valemetostat for TCL provide encouraging collateral data to suggest a class effect. Results from CTEP 10500 supports the biologic rationale for dual targeting with EZH2 and HDAC inhibitors supporting further evaluation in TCL. Funding by NCI-UM1CA186689/ETCTN/CRADA with Epizyme and Acrotech; led by Columbia University.
DISCLOSURES
Jennifer Effie Amengual, MD: AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)